BI 655066 (Risankizumab) Compared to Placebo in Japanese Patients With Moderate to Severe Chronic Plaque Psoriasis
Status:
Completed
Trial end date:
2018-06-20
Target enrollment:
Participant gender:
Summary
This is a randomized double blind, double dummy, placebo controlled, parallel design study
that is being performed to assess the safety and efficacy of BI 655066 (risankizumab).